ERBB2 and breast carcinoma: Our data showing that selumetinib-induced ErbB2 degradation is proteasome-independent (Figure 5B) indicate that the mechanism outlined above is unlikely involved in the effect of selumetinib on ErbB2 in breast cancer cells detached from the ECM.